Lysosomal protein transmembrane 5 (LAPTM5)

Lysosomal protein transmembrane 5 (LAPTM5) is a multispanning membrane protein localized primarily to lysosomes and late endosomal compartments, with five transmembrane domains and several motifs (PY and UIM) that interact with ubiquitin ligases and adaptor proteins. LAPTM5 is preferentially expressed in hematopoietic/immune cells but is also detected in other tissues including the heart. It plays vital roles in cellular homeostasis by regulating lysosome-dependent degradation of immune cell receptors, modulating cytokine release and inflammation through the NF-κB and MAPK pathways (as both positive and negative regulator depending on cell type), mediating protein sorting from Golgi to lysosome, and influencing autophagy and cell death mechanisms including apoptosis and lysosomal cell death. LAPTM5’s dysfunction or altered expression has been implicated in cancers, cardiovascular diseases (notably cardiac hypertrophy), and immune-related diseases. It is not currently the primary target of any clinical drug, but its role in disease pathogenesis and signaling makes it a target of preclinical interest for future therapeutic strategies.

Other names

Lysosomal-associated transmembrane protein 5KIAA0085CLAST6Retinoic acid-inducible E3 proteinCD40-ligand-activated specific transcriptLysosomal multispanning membrane protein 5

Not directly targeted by drugs; theoretically, modulation of LAPTM5 could affect: - Lysosomal trafficking and degradation of immune receptors - Regulation of inflammatory signaling (NF-κB, MAPK) and cell death pathways - Modulation of autophagy and lysosomal function